The China Mail - Study shows how fast kilos return after ending weight-loss drugs

USD -
AED 3.672503
AFN 62.999752
ALL 81.531366
AMD 374.809235
ANG 1.789731
AOA 916.999856
ARS 1397.464498
AUD 1.405323
AWG 1.8
AZN 1.702513
BAM 1.653625
BBD 2.005183
BDT 121.658698
BGN 1.647646
BHD 0.377031
BIF 2953.058153
BMD 1
BND 1.260209
BOB 6.878971
BRL 5.129201
BSD 0.995574
BTN 90.455597
BWP 13.102681
BYN 2.854655
BYR 19600
BZD 2.002224
CAD 1.367531
CDF 2135.00043
CHF 0.773361
CLF 0.02167
CLP 855.64987
CNY 6.84425
CNH 6.837065
COP 3696.74
CRC 472.126047
CUC 1
CUP 26.5
CVE 93.22883
CZK 20.5396
DJF 177.284007
DKK 6.33128
DOP 60.503832
DZD 129.936029
EGP 47.819398
ERN 15
ETB 154.305402
EUR 0.8472
FJD 2.19355
FKP 0.738003
GBP 0.73935
GEL 2.669984
GGP 0.738003
GHS 10.61269
GIP 0.738003
GMD 72.99984
GNF 8731.420261
GTQ 7.637383
GYD 208.288416
HKD 7.822295
HNL 26.339797
HRK 6.382304
HTG 130.654244
HUF 317.794986
IDR 16762
ILS 3.101765
IMP 0.738003
INR 90.88125
IQD 1304.180565
IRR 1310670.000154
ISK 121.419783
JEP 0.738003
JMD 155.216511
JOD 0.708985
JPY 155.984506
KES 128.900162
KGS 87.449568
KHR 3993.269865
KMF 417.000344
KPW 899.996575
KRW 1426.40993
KWD 0.306602
KYD 0.829603
KZT 499.714644
LAK 21321.766922
LBP 89141.320161
LKR 307.972623
LRD 182.686739
LSL 15.826453
LTL 2.95274
LVL 0.60489
LYD 6.299805
MAD 9.138395
MDL 17.053693
MGA 4185.214778
MKD 52.207611
MMK 2100.062479
MNT 3568.923913
MOP 8.019802
MRU 39.693592
MUR 46.330348
MVR 15.460258
MWK 1726.337683
MXN 17.17905
MYR 3.887021
MZN 63.904978
NAD 15.826453
NGN 1349.920068
NIO 36.635271
NOK 9.55205
NPR 144.728954
NZD 1.670075
OMR 0.384517
PAB 0.995574
PEN 3.343437
PGK 4.281583
PHP 57.635043
PKR 278.306721
PLN 3.575655
PYG 6412.256338
QAR 3.6293
RON 4.316602
RSD 99.497014
RUB 77.050619
RWF 1454.510097
SAR 3.750582
SBD 8.048447
SCR 13.667069
SDG 601.496279
SEK 9.040455
SGD 1.263545
SHP 0.750259
SLE 24.450464
SLL 20969.49935
SOS 567.920963
SRD 37.811968
STD 20697.981008
STN 20.714612
SVC 8.711165
SYP 110.750917
SZL 15.828567
THB 31.058974
TJS 9.442859
TMT 3.5
TND 2.890081
TOP 2.40776
TRY 43.88325
TTD 6.758065
TWD 31.224201
TZS 2561.162029
UAH 43.084038
UGX 3584.065746
UYU 38.199597
UZS 12133.740863
VES 410.571865
VND 26071.5
VUV 118.964651
WST 2.714572
XAF 554.610289
XAG 0.011463
XAU 0.000193
XCD 2.70255
XCG 1.794231
XDR 0.689757
XOF 554.610289
XPF 100.834084
YER 238.450384
ZAR 15.876345
ZMK 9001.200147
ZMW 18.765827
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • RYCEF

    0.1600

    17.9

    +0.89%

  • BCE

    -0.4000

    25.63

    -1.56%

  • BCC

    -3.0400

    83.62

    -3.64%

  • CMSC

    0.0160

    23.896

    +0.07%

  • CMSD

    0.0100

    23.69

    +0.04%

  • JRI

    -0.0300

    13.14

    -0.23%

  • NGG

    1.5500

    93.93

    +1.65%

  • GSK

    0.4200

    59.54

    +0.71%

  • RIO

    2.6700

    100.78

    +2.65%

  • RELX

    1.4700

    32.69

    +4.5%

  • VOD

    0.1600

    15.86

    +1.01%

  • BP

    -0.2100

    38.09

    -0.55%

  • BTI

    1.1200

    63.03

    +1.78%

  • AZN

    -0.8200

    205.79

    -0.4%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: © AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Parker--ThChM